192 related articles for article (PubMed ID: 29556791)
1. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
3. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
4. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
5. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS.
Simon ES; Reyna D; Lister RJ; Harteg C; Lipka E
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Mar; 1080():82-89. PubMed ID: 29482122
[TBL] [Abstract][Full Text] [Related]
7. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic amifostine prevents a pathologic vascular response in a murine model of expander-based breast reconstruction.
Polyatskaya Y; Nelson NS; Rodriguez JJ; Zheutlin AR; Deshpande SS; Felice PA; Donneys A; Buchman SR
J Plast Reconstr Aesthet Surg; 2016 Feb; 69(2):234-40. PubMed ID: 26631290
[TBL] [Abstract][Full Text] [Related]
9. A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Soref CM; Hacker TA; Fahl WE
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e701-7. PubMed ID: 22330992
[TBL] [Abstract][Full Text] [Related]
10. Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.
Varghese JJ; Schmale IL; Mickelsen D; Hansen ME; Newlands SD; Benoit DSW; Korshunov VA; Ovitt CE
J Dent Res; 2018 Oct; 97(11):1252-1259. PubMed ID: 29634396
[TBL] [Abstract][Full Text] [Related]
11. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner HS; Shaw LM
J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
Li C; Wang S; Huang T; Chen N; Ou M
Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
14. Radioprotection With Amifostine Enhances Bone Strength and Regeneration and Bony Union in a Rat Model of Mandibular Distraction Osteogenesis.
Tchanque-Fossuo CN; Donneys A; Deshpande SS; Sarhaddi D; Nelson NS; Monson LA; Dahle SE; Goldstein SA; Buchman SR
Ann Plast Surg; 2018 Feb; 80(2):176-180. PubMed ID: 28930778
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
16. Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Clémenson C; Liu W; Bricout D; Soyez-Herkert L; Chargari C; Mondini M; Haddad R; Wang-Zhang X; Benel L; Bloy C; Deutsch E
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1141-1152. PubMed ID: 31063799
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of amifostine.
Shaw LM; Bonner H; Lieberman R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
19. Alternate delivery route for amifostine as a radio-/chemo-protecting agent.
Praetorius NP; Mandal TK
J Pharm Pharmacol; 2008 Jul; 60(7):809-15. PubMed ID: 18549666
[TBL] [Abstract][Full Text] [Related]
20. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
